The increase in the pool means Taiho Ventures’ commitment to support of innovative biotech startups pursuing drug discovery activities based on state-of-the-art science. Taiho Pharmaceutical also aims to accelerate its open innovation through these investment efforts.
Established by CEO and President Sakae Asanuma in 2016, Taiho Ventures is the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharma focusing on oncology, allergy and immunology. Since its inception in 2016, the arm has been actively searching for opportunities to invest in promising startup companies around the world that conduct innovative first-in-class drug discovery and establish unique platform technologies, primarily in the oncology field.
The firm has built an innovative investment portfolio consisting of more than 25 companies, including Arcus Biosciences, Cullinan Pearl, Dren Bio, Orna Therapeutics and Werewolf Therapeutics.